Expression of transforming growth factor beta1 gene, basic fibroblast growth factor gene and hydroxyproline in diabetes-induced bladder dysfunction in a rat model.
OBJECTIVE
To investigate the content of hydroxyproline (Hyp) and the expression of transforming growth factor beta1 (TGF beta1) and basic fibroblast growth factor (bFGF) in the bladder 8 weeks after diabetes induction.


METHODS
Thirty wistar rats were divided into three groups: control (n = 10), streptozotocin-induced diabetic group (n = 10), TAD group (n = 10; diabetic rats were fed with Tadenan 100 mg kg(-1) day(-1)). Eight weeks later, the bladders were dissected. RT-PCR, immunohistochemistry, and ELISA were used to detect the expression of TGF beta1 and bFGF in the bladder. Also hydroxyproline (Hyp) was measured using a method based on alkaline hydrolysis.


RESULTS
The content of hydroxyproline in the diabetic group was greater than that of control group (P < 0.05); we found significantly increased expression of TGF beta1 mRNA and bFGF mRNA in the bladder from the diabetic group compared with the control group; immunohistochemical and ELISA studies showed a statistically significant increased expression of TGF beta1 protein and bFGF protein in the bladder from the diabetic group compared with the control group (P < 0.05). The content of hydroxyproline in TAD group was less than that of diabetic group (P < 0.05); mRNA expression of TGF beta1 and bFGF greatly decreased in TAD group compared with that of the diabetic group; immunohistochemical and ELISA studies showed decreased levels of TGF beta1 protein and bFGF protein in the bladder from TAD group compared with the diabetic group (P < 0.05).


CONCLUSIONS
Rats with streptozoticin-induced diabetes mellitus showed significant increase in hydroxyproline, TGF beta1 and bFGF levels in their bladders, which may be an important mechanism inducing diabetic cystopathy. Tadenan could effectively reduce hydroxyproline, TGF beta1, and bFGF levels.
Yongzhi
Li
L
Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Benkang
Shi
S
Jianping
Zhang
Z
Lingxia
Ran
R
Wei
Bian
B
Yaofeng
Zhu
Z
Keqin
Zhang
Z
Laudon
Vincent
V
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D005233:Fatty Alcohols / Q000494:pharmacology / Q000627:therapeutic use; D016222:Fibroblast Growth Factor 2 / Q000235:genetics / Q000378:metabolism*; D006909:Hydroxyproline / Q000378:metabolism*; D008297:Male; D010936:Plant Extracts; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D053773:Transforming Growth Factor beta1 / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation; D001743:Urinary Bladder / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D001745:Urinary Bladder Diseases / Q000209:etiology / Q000235:genetics / Q000378:metabolism* / Q000517:prevention & control
D005233:Fatty Alcohols; D010936:Plant Extracts; D012333:RNA, Messenger; C009375:Tadenan; D053773:Transforming Growth Factor beta1; D016222:Fibroblast Growth Factor 2; D006909:Hydroxyproline